Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

First Immunotherapy Receives FDA Approval for Breast Cancer Treatment

First Immunotherapy Receives FDA Approval for Breast Cancer Treatment
In this article

On 8 March 2019, the United States Food and Drug Administration (FDA), for PD-L1-positive, unresectable locally advanced or metastatic disease in triple-negative breast cancer as first-line treatment, nab-paclitaxel chemotherapy combined with an immunotherapy drug, atezolizumab (Tecentriq), received accelerated approval.

Note: Of breast cancers, % 15 Are Approximately Triple-Negative Breast Cancer.

Atezolizumab became the first immunotherapy drug approved for treating breast cancer.

The new approval was based on results presented at ESMO 2018 from the IMpassion130 named clinical trial progression-free (without progression) survival (progression-free survival, PFS) results.

The study enrolled 902 patients with unresectable locally advanced or metastatic triple-negative breast cancer. Patients were randomly assigned to two arms: 451 received atezolizumab plus nap-paclitaxel, while the other 451 received placebo plus nab-paclitaxel.

Results of the IMpassion130 Study

In the overall patient group, median progression-free survival was 7.2 months when atezolizumab was added to chemotherapy, compared with 5.5 months in the placebo plus chemotherapy arm.

Atezolizumab also increased median overall survival, but statistical significance was not reached at the interim analysis (21.3 and 17.6 months).

Researchers also performed a subgroup analysis among patients with tumor-infiltrating immune system cells showing PD-L1 levels ≥ % 1. Among patients with triple-negative breast cancer, approximately % 40 had PD-L1 positivity . This analysis included 185 patients in the atezolizumab group and 184 in the placebo group.

The study’s most striking results were in this PD-L1-positive group;

  • Atezolizumab significantly reduced the risk of disease progression or death.
  • Median progression-free survival was 7.5 months in the immunotherapy arm and 5.0 months in the placebo arm.
  • Adding immunotherapy to chemotherapy reduced the risk of progression by % 38.
  • The objective response rate was % 53 in the immunotherapy arm and % 33 in the placebo arm.
  • Immunotherapy also prolonged median overall survival: 25.0 months versus 15.5 months.

Following these striking findings, immunotherapy plus chemotherapy may become the new standard for PD-L1-positive triple-negative breast cancer. However, it is too early to draw a definitive conclusion because overall survival data for this combination are not yet fully mature.

Administration and Dose:

Atezolizumab was given in every 28-day cycle on days 1 and 15 by intravenous (IV) infusion at a fixed dose of 840 mg over 60 minutes, until disease progression or unacceptable adverse effects. Following immunotherapy, nab-paclitaxel was given in every 28-day cycle on days 1., 8., and 15. by IV infusion at an initial dose of 100 mg / m2.

During the study, progression or death occurred in 358 patients (% 79,4) in the atezolizumab group and 378 (% 83,8) in the placebo group.

Adverse Effects

Researchers reported that adverse effects were consistent with the safety profiles of the study drugs; atezolizumab plus nab-paclitaxel produced no new safety signals.

Serious adverse effects were reported in % 23 of the atezolizumab group and % 18 of the placebo group (grade 3. and 4.). The most common serious adverse effects were neutropenia (% 8); peripheral neuropathy (% 6); fatigue (% 4); and anemia (% 3).

Sources

FDA Approves First Immunotherapy for Breast Cancer - Medscape - Mar 08, 2019.
DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

First Immunotherapy Receives FDA Approval for Breast Cancer Treatment

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy